Fibromyalgia syndrome in need of effective treatments

Journal of Pharmacology and Experimental Therapeutics

Volumn 355, Issue 2, 2015, Pages 255-263

  Theoharides, Theoharis C ^a,b   Tsilioni, Irene ^a   Arbetman, Lauren ^a   Panagiotidou, Smaro ^a   Stewart, Julia M ^a   Gleason, Rae M ^c   Russell, Irwin J ^d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

^c National Fibromyalgia and Chronic Pain Association   (United States)

^d Arthritis and Osteoporosis Center of South Texas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARNITINE; CYCLOBENZAPRINE; DULOXETINE; FLAVONOID; GABAPENTIN; LUTEOLIN; MILNACIPRAN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PLACEBO; PREGABALIN; QUERCETIN; SEROTONIN UPTAKE INHIBITOR; TETRAMETHOXYLUTEOLIN; TRICYCLIC ANTIDEPRESSANT AGENT; UBIDECARENONE; UNCLASSIFIED DRUG; MUSCLE RELAXANT AGENT;

ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BEDTIME DOSAGE; BEHAVIOR THERAPY; COGNITIVE THERAPY; DISEASE CLASSIFICATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; EXERCISE; FIBROMYALGIA; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEREDITY; HUMAN; LOW DRUG DOSE; MENTAL STRESS; NERVOUS SYSTEM INFLAMMATION; NOCICEPTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATIENT EDUCATION; PRIORITY JOURNAL; PSYCHOTRAUMA; QIGONG; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SUPPLEMENTATION; SYMPTOM; TAI CHI; THERAPY EFFECT; YOGA; DIETARY SUPPLEMENT; SYNDROME;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; DIETARY SUPPLEMENTS; FIBROMYALGIA; HUMANS; NEUROMUSCULAR AGENTS; PATIENT EDUCATION AS TOPIC; SYNDROME;

EID: 84946750017     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.227298     Document Type: Review

References (162)

1. Abbadie C (2005) Chemokines, chemokine receptors and pain. Trends Immunol 26: 529-534.
2. Abraham SN and St John AL (2010) Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10:440-452.
3. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, and Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 187:116-126.
4. Alvarez P, Green PG, and Levine JD (2014) Role for monocyte chemoattractant protein-1 in the induction of chronic muscle pain in the rat. Pain 155:1161-1167.
5. Arnold LM, Fan J, Russell IJ, Yunus MB, Khan MA, Kushner I, Olson JM, and Iyengar SK (2013) The fibromyalgia family study: A genome-wide linkage scan study. Arthritis Rheum 65:1122-1128.
6. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, and Wernicke JF (2005) A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119:5-15.
7. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, Martin SA, Barrett JA, and Haig G (2008) A 14-week, randomized, double-blinded, placebocontrolled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 9: 792-805.
8. Arranz LI, Canela MA, and Rafecas M (2012) Dietary aspects in fibromyalgia patients: results of a survey on food awareness, allergies, and nutritional supplementation. Rheumatol Int 32:2615-2621.
9. Asadi S and Theoharides TC (2012) Corticotropin-releasing hormone and extracellular mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth factor release, which is inhibited by luteolin. J Neuroinflammation 9:85.
10. Bazzichi L, Rossi A, Massimetti G, Giannaccini G, Giuliano T, De Feo F, Ciapparelli A, Dell'Osso L, and Bombardieri S (2007) Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol 25:225-230.
11. Behm FG, Gavin IM, Karpenko O, Lindgren V, Gaitonde S, Gashkoff PA, and Gillis BS (2012) Unique immunologic patterns in fibromyalgia. BMC Clin Pathol 12:25.
12. Bennett R and Nelson D (2006) Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol 2:416-424.
13. Bernardy K, Füber N, Köllner V, and Häuser W (2010) Efficacy of cognitivebehavioral therapies in fibromyalgia syndrome - A systematic review and metaanalysis of randomized controlled trials. J Rheumatol 37:1991-2005.
14. Bessa J, Meyer CA, de Vera Mudry MC, Schlicht S, Smith SH, Iglesias A, and Cote- Sierra J (2014) Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation. J Autoimmun 55:33-41.
15. Blanco I, Béritze N, Argüelles M, Cárcaba V, Fernández F, Janciauskiene S, Oikonomopoulou K, de Serres FJ, Fernández-Bustillo E, and Hollenberg MD (2010) Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. Clin Rheumatol 29:1403-1412.
16. Boomershine CS and Crofford LJ (2009) A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol 5:191-199.
17. Bote ME, García JJ, Hinchado MD, and Ortega E (2012) Inflammatory/stress feedback dysregulation in women with fibromyalgia. Neuroimmunomodulation 19: 343-351.
18. Bote ME, Garcia JJ, Hinchado MD, and Ortega E (2013) Fibromyalgia: Antiinflammatory and stress responses after acute moderate exercise. PLoS One 8: e74524.
19. Bozkurt M, Caglayan M, Oktayoglu P, Em S, Batmaz I, Sariyildiz MA, Nas K, Ucar D, Yüksel H, and Sarac AJ (2014) Serum prolidase enzyme activity and oxidative status in patients with fibromyalgia. Redox Rep 19:148-153.
20. Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, Saraiva F, Nacci F, Thomas E, and Caubère JP, et al. (2010) Prevalence of fibromyalgia: A survey in five European countries. Semin Arthritis Rheum 39:448-453.
21. Buskila D, Atzeni F, and Sarzi-Puttini P (2008) Etiology of fibromyalgia: The possible role of infection and vaccination. Autoimmun Rev 8:41-43.
22. Buskila D, Sarzi-Puttini P, and Ablin JN (2007) The genetics of fibromyalgia syndrome. Pharmacogenomics 8:67-74.
23. Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, Cetrulo CL, and Theoharides TC (2005) Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 174:7665-7675.
24. Carvalho LS, Correa H, Silva GC, Campos FS, Baião FR, Ribeiro LS, Faria AM, and d'Avila Reis D (2008) May genetic factors in fibromyalgia help to identify patients with differentially altered frequencies of immune cells? Clin Exp Immunol 154:346-352.
25. Cazarolli LH, Zanatta L, Alberton EH, Figueiredo MS, Folador P, Damazio RG, Pizzolatti MG, and Silva FR (2008) Flavonoids: prospective drug candidates. Mini Rev Med Chem 8:1429-1440.
26. Chan JK, Roth J, Oppenheim JJ, Tracey KJ, Vogl T, Feldmann M, Horwood N, and Nanchahal J (2012) Alarmins: Awaiting a clinical response. J Clin Invest 122: 2711-2719.
27. Charo IF and Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610-621.
28. Chatterjea D and Martinov T (2015) Mast cells: versatile gatekeepers of pain. Mol Immunol 63:38-44.
29. Clauw DJ (2010) Pain management: fibromyalgia drugs are 'as good as it gets' in chronic pain. Nat Rev Rheumatol 6:439-440.
30. Clauw DJ (2014) Fibromyalgia: A clinical review. JAMA 311:1547-1555.
31. Clauw DJ, Arnold LM, and McCarberg BH; FibroCollaborative (2011) The science of fibromyalgia. Mayo Clin Proc 86:907-911.
32. Clemons A, Vasiadi M, Kempuraj D, Kourelis T, Vandoros G, and Theoharides TC (2011) Amitriptyline and prochlorperazine inhibit proinflammatory mediator release from human mast cells: possible relevance to chronic fatigue syndrome. J Clin Psychopharmacol 31:385-387.
33. Cohen H, Buskila D, Neumann L, and Ebstein RP (2002) Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum 46: 845-847.
34. Cohen H, Neumann L, Glazer Y, Ebstein RP, and Buskila D (2009) The relationship between a common catechol-O-methyltransferase (COMT) polymorphism val(158) met and fibromyalgia. Clin Exp Rheumatol 27(5, Suppl 56)S51-S56.
35. Conti P, Reale M, Barbacane RC, Letourneau R, and Theoharides TC (1998) Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effects in genetically mast cell-deficient W/WV mice. FASEB J 12:1693-1700.
36. Conti P and Theoharides TC (1994) Monocyte chemotactic protein-1 (MCP-1) is active on mast cells and causes clump formation. Int J Immunopathol Pharmacol 7: 149-151.
37. Cordero MD, Díaz-Parrado E, Carrión AM, Alfonsi S, Sánchez-Alcazar JA, Bullón P, Battino M, and de Miguel M (2013) Is inflammation a mitochondrial dysfunctiondependent event in fibromyalgia? Antioxid Redox Signal 18:800-807.
38. Cordero MD, Cano-García FJ, Alcocer-Gómez E, De Miguel M, and Sánchez-Alcázar JA (2012a) Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q10 effect on clinical improvement. PLoS One 7:e35677.
39. Cordero MD, Cotán D, del-Pozo-Martín Y, Carrión AM, de Miguel M, Bullón P, and Sánchez-Alcazar JA (2012b) Oral coenzyme Q10 supplementation improves clinical symptoms and recovers pathologic alterations in blood mononuclear cells in a fibromyalgia patient. Nutrition 28:1200-1203.
40. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP Jr, LaMoreaux LK, Martin SA, and Sharma U Pregabalin 1008-105 Study Group (2005) Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52:1264-1273.
41. Crofford LJ, Young EA, Engleberg NC, Korszun A, Brucksch CB, McClure LA, Brown MB, and Demitrack MA (2004) Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun 18:314-325.
42. Desmeules JA, Cedraschi C, Rapiti E, Baumgartner E, Finckh A, Cohen P, Dayer P, and Vischer TL (2003) Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 48:1420-1429.
43. Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliodis D, Dobner P, and Theoharides TC (2006) Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci USA 103:7759-7764.
44. Dudeck A, Suender CA, Kostka SL, von Stebut E, and Maurer M (2011) Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function. Eur J Immunol 41:1883-1893.
45. Dudek DM, Arnold LM, and Lyengar SK (2003) Genetic linkage of fibromyalgia ot the serotonin receptor 2A region of chromosome 13 and the HLA region on chromosome 6. Am J Hum Genet 75:468.
46. Eisen SA, Kang HK, Murphy FM, Blanchard MS, Reda DJ, Henderson WG, Toomey R, Jackson LW, Alpern R, and Parks BJ, et al.; Gulf War Study Participating Investigators (2005) Gulf War veterans' health: medical evaluation of a U.S. cohort. Ann Intern Med 142:881-890.
47. Enoksson M, Lyberg K, Möller-Westerberg C, Fallon PG, Nilsson G, and Lunderius-Andersson C (2011) Mast cells as sensors of cell injury through IL-33 recognition. J Immunol 186:2523-2528.
48. Esposito P, Chandler N, Kandere K, Basu S, Jacobson S, Connolly R, Tutor D, and Theoharides TC (2002) Corticotropin-releasing hormone and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 303:1061-1066.
49. Ferrari R and Russell AS (2013) A questionnaire using the modified 2010 American College of Rheumatology criteria for fibromyalgia: specificity and sensitivity in clinical practice. J Rheumatol 40:1590-1595.
50. Finan PH, Zautra AJ, Davis MC, Lemery-Chalfant K, Covault J, and Tennen H (2011) COMT moderates the relation of daily maladaptive coping and pain in fibromyalgia. Pain 152:300-307.
51. Flodin P, Martinsen S, Löfgren M, Bileviciute-Ljungar I, Kosek E, and Fransson P (2014) Fibromyalgia is associated with decreased connectivity between pain- And sensorimotor brain areas. Brain Connect 4:587-594.
52. Frossi B, De Carli M, Daniel KC, Rivera J, and Pucillo C (2003) Oxidative stress stimulates IL-4 and IL-6 production in mast cells by an APE/Ref-1-dependent pathway. Eur J Immunol 33:2168-2177.
53. Fux M, Pecaric-Petkovic T, Odermatt A, Hausmann OV, Lorentz A, Bischoff SC, Virchow JC, and Dahinden CA (2014) IL-33 is a mediator rather than a trigger of the acute allergic response in humans. Allergy 69:216-222.
54. Galli SJ, Borregaard N, and Wynn TA (2011) Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol 12:1035-1044.
55. Galli SJ, Tsai M, and Piliponsky AM (2008) The development of allergic inflammation. Nature 454:445-454.
56. Garcia-Campayo J, Magdalena J, Magallón R, Fernández-García E, Salas M, and Andrés E (2008) A meta-analysis of the efficacy of fibromyalgia treatment according to level of care. Arthritis Res Ther 10:R81.
57. Gaskell H, Moore RA, Derry S, and Stannard C (2014) Oxycodone for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 6:CD010692.
58. Geenen R, Jacobs JW, and Bijlsma JW (2002) Evaluation and management of endocrine dysfunction in fibromyalgia. Rheum Dis Clin North Am 28:389-404.
59. Geiss A, Rohleder N, and Anton F (2012) Evidence for an association between an enhanced reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity in patients with fibromyalgia. Psychoneuroendocrinology 37:671-684.
60. Giovengo SL, Russell IJ, and Larson AA (1999) Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 26: 1564-1569.
61. Goldenberg DL, Burckhardt C, and Crofford L (2004) Management of fibromyalgia syndrome. JAMA 292:2388-2395.
62. Greenwood-Van Meerveld B, Mohammadi E, Tyler K, Pietra C, Bee LA, and Dickenson A (2014) Synergistic effect of 5-hydroxytryptamine 3 and neurokinin 1 receptor antagonism in rodent models of somatic and visceral pain. J Pharmacol Exp Ther 351:146-152.
63. Griffin GK, Newton G, Tarrio ML, Bu DX, Maganto-Garcia E, Azcutia V, Alcaide P, Grabie N, Luscinskas FW, and Croce KJ, et al. (2012) IL-17 and TNF-a sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol 188:6287-6299.
64. Grosso C, Valentão P, Ferreres F, and Andrade PB (2013) The use of flavonoids in central nervous system disorders. Curr Med Chem 20:4694-4719.
65. Harris RE, Napadow V, Huggins JP, Pauer L, Kim J, Hampson J, Sundgren PC, Foerster B, Petrou M, and Schmidt-Wilcke T, et al. (2013) Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. Anesthesiology 119:1453-1464.
66. Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, and Lines TC (2007) A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 45:2179-2205.
67. Häuser W, Bernardy K, Arnold B, Offenbächer M, and Schiltenwolf M (2009a) Efficacy of multicomponent treatment in fibromyalgia syndrome: A meta-analysis of randomized controlled clinical trials. Arthritis Rheum 61:216-224.
68. Häuser W, Bernardy K, Uçeyler N, and Sommer C (2009b) Treatment of fibromyalgia syndrome with antidepressants: A meta-analysis. JAMA 301:198-209.
69. Häuser W, Bernardy K, Uçeyler N, and Sommer C (2009c) Treatment of fibromyalgia syndrome with gabapentin and pregabalin-a meta-analysis of randomized controlled trials. Pain 145:69-81.
70. Häuser W, Petzke F, Üçeyler N, and Sommer C (2011) Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: A systematic review with meta-analysis. Rheumatology (Oxford) 50: 532-543.
71. Heffez DS, Ross RE, Shade-Zeldow Y, Kostas K, Shah S, Gottschalk R, Elias DA, Shepard A, Leurgans SE, and Moore CG (2004) Clinical evidence for cervical myelopathy due to Chiari malformation and spinal stenosis in a non-randomized group of patients with the diagnosis of fibromyalgia. Eur Spine J 13:516-523.
72. Héron A and Dubayle D (2013) A focus on mast cells and pain. J Neuroimmunol 264: 1-7.
73. Holman AJ (2012) Using dynamic MRI to diagnose neck pain: The import of positional cervical cord compression (PC3). Pract Pain Manag 12:51-55.
74. Hornig M, Montoya JG, Klimas NG, Levine S, Felsenstein D, Bateman L, Peterson DL, Gottschalk CG, Schultz AF, and Che X, et al. (2015) Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv 1: e1400121.
75. Hox V, Desai A, Bandara G, Gilfillan AM, Metcalfe DD, and Olivera A (2015) Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production. J Allergy Clin Immunol 135:729-36.e5.
76. Iqbal R, Mughal MS, Arshad N, and Arshad M (2011) Pathophysiology and antioxidant status of patients with fibromyalgia. Rheumatol Int 31:149-152.
77. Izzi V, Masuelli L, Tresoldi I, Sacchetti P, Modesti A, Galvano F, and Bei R (2012) The effects of dietary flavonoids on the regulation of redox inflammatory networks. Front Biosci (Landmark Ed) 17:2396-2418.
78. Jäger AK and Saaby L (2011) Flavonoids and the CNS. Molecules 16:1471-1485.
79. Jensen KB, Loitoile R, Kosek E, Petzke F, Carville S, Fransson P, Marcus H, Williams SC, Choy E, and Mainguy Y, et al. (2012) Patients with fibromyalgia display less functional connectivity in the brain's pain inhibitory network. Mol Pain 8:32.
80. Kadetoff D, Lampa J, Westman M, Andersson M, and Kosek E (2012) Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol 242:33-38.
81. Kawanishi S, Oikawa S, and Murata M (2005) Evaluation for safety of antioxidant chemopreventive agents. Antioxid Redox Signal 7:1728-1739.
82. Kawikova I and Askenase PW (2015) Diagnostic and therapeutic potentials of exosomes in CNS diseases. Brain Res 1617:63-71.
83. Kempuraj D, Tagen M, Iliopoulou BP, Clemons A, Vasiadi M, Boucher W, House M, Wolfberg A, and Theoharides TC (2008) Luteolin inhibits myelin basic proteininduced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells. Br J Pharmacol 155:1076-1084.
84. Kenna TJ and Brown MA (2013) The role of IL-17-secreting mast cells in inflammatory joint disease. Nat Rev Rheumatol 9:375-379.
85. Kim SH, Lee Y, Lee S, and Mun CW (2013) Evaluation of the effectiveness of pregabalin in alleviating pain associated with fibromyalgia: using functional magnetic resonance imaging study. PLoS One 8:e74099.
86. Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, and Nagai H (2000) Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy 30:501-508.
87. Kovats S (2015) Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol 294:63-69.
88. Kuchinad A, Schweinhardt P, Seminowicz DA, Wood PB, Chizh BA, and Bushnell MC (2007) Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci 27:4004-4007.
89. Lewin GR, Lechner SG, and Smith ES (2014) Nerve growth factor and nociception: from experimental embryology to new analgesic therapy. Handbook Exp Pharmacol 220:251-282.
90. Liu Y, Ho RC, and Mak A (2012) The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis. Int J Rheum Dis 15:183-187.
91. Lucas HJ, Brauch CM, Settas L, and Theoharides TC (2006) Fibromyalgia-new concepts of pathogenesis and treatment. Int J Immunopathol Pharmacol 19:5-10.
92. Lunn MP, Hughes RA, and Wiffen PJ (2014) Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 1:CD007115.
93. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, and Bosmans E (2009) Lower plasma coenzyme Q10 in depression: A marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuroendocrinol Lett 30:462-469.
94. McBeth J and Mulvey MR (2012) Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria. Nat Rev Rheumatol 8:108-116.
95. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, and Cua DJ (2007) TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8:1390-1397.
96. McLean SA, Diatchenko L, Lee YM, Swor RA, Domeier RM, Jones JS, Jones CW, Reed C, Harris RE, and Maixner W, et al. (2011) Catechol O-methyltransferase haplotype predicts immediate musculoskeletal neck pain and psychological symptoms after motor vehicle collision. J Pain 12:101-107.
97. McLean SA, Williams DA, Stein PK, Harris RE, Lyden AK, Whalen G, Park KM, Liberzon I, Sen A, and Gracely RH, et al. (2006) Cerebrospinal fluid corticotropinreleasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology 31:2776-2782.
98. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, and Sharma U (2008) A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35:502-514.
99. Meng X, Zhang Y, Lao L, Saito R, Li A, Bäckman CM, Berman BM, Ren K, Wei PK, and Zhang RX (2013) Spinal interleukin-17 promotes thermal hyperalgesia and NMDA NR1 phosphorylation in an inflammatory pain rat model. Pain 154: 294-305.
100. Middleton E Jr, Kandaswami C, and Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673-751.
101. Mist SD, Firestone KA, and Jones KD (2013) Complementary and alternative exercise for fibromyalgia: A meta-analysis. J Pain Res 6:247-260.
102. Moldofsky H, Harris HW, Archambault WT, Kwong T, and Lederman S (2011) Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: A double-blind randomized placebocontrolled study. J Rheumatol 38:2653-2663.
103. Moore RA, Wiffen PJ, Derry S, Toelle T, and Rice AS (2014) Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 4: CD007938.
104. Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, and Galli SJ (2005) Mast cells enhance T cell activation: importance of mast cell-derived TNF. Proc Natl Acad Sci USA 102:6467-6472.
105. Neyal M, Yimenicioglu F, Aydeniz A, Taskin A, Saglam S, Cekmen M, Neyal A, Gursoy S, Erel O, and Balat A (2013) Plasma nitrite levels, total antioxidant status, total oxidant status, and oxidative stress index in patients with tension-type headache and fibromyalgia. Clin Neurol Neurosurg 115:736-740.
106. Nugraha B, Karst M, Engeli S, and Gutenbrunner C (2012) Brain-derived neurotrophic factor and exercise in fibromyalgia syndrome patients: A mini review. Rheumatol Int 32:2593-2599.
107. Nugraha B, Korallus C, Kielstein H, and Gutenbrunner C (2013) CD31CD561 natural killer T cells in fibromyalgia syndrome patients: Association with the intensity of depression. Clin Exp Rheumatol 31;(Suppl 79):S9-S15.
108. Offenbaecher M, Bondy B, de Jonge S, Glatzeder K, Krüger M, Schoeps P, and Ackenheil M (1999) Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 42:2482-2488.
109. Olszewski MB, Groot AJ, Dastych J, and Knol EF (2007) TNF trafficking to human mast cell granules: mature chain-dependent endocytosis. J Immunol 178: 5701-5709.
110. Pang X, Cotreau-Bibbo MM, Sant GR, and Theoharides TC (1995) Bladder mast cell expression of high affinity oestrogen receptors in patients with interstitial cystitis. Br J Urol 75:154-161.
111. Paras ML, Murad MH, Chen LP, Goranson EN, Sattler AL, Colbenson KM, Elamin MB, Seime RJ, Prokop LJ, and Zirakzadeh A (2009) Sexual abuse and lifetime diagnosis of somatic disorders: A systematic review and meta-analysis. JAMA 302: 550-561.
112. Pernambuco AP, Schetino LP, Alvim CC, Murad CM, Viana RS, Carvalho LS, and Reis DA (2013) Increased levels of IL-17A in patients with fibromyalgia. Clin Exp Rheumatol 31(6, Suppl 79)S60-S63.
113. Pollack S (2015) Mast cells in fibromyalgia. Clin Exp Rheumatol 33;(Suppl 88):S140.
114. Porter NS, Jason LA, Boulton A, Bothne N, and Coleman B (2010) Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia. J Altern Complement Med 16:235-249.
115. Potvin S, Larouche A, Normand E, de Souza JB, Gaumond I, Grignon S, and Marchand S (2009) DRD3 Ser9Gly polymorphism is related to thermal pain perception and modulation in chronic widespread pain patients and healthy controls. J Pain 10:969-975.
116. Rivera J, Fierro NA, Olivera A, and Suzuki R (2008) New insights on mast cell activation via the high affinity receptor for IgE. Adv Immunol 98:85-120.
117. Rodriguez-Pintó I, Agmon-Levin N, Howard A, and Shoenfeld Y (2014) Fibromyalgia and cytokines. Immunol Lett 161:200-203.
118. Romero-Sanchez C, Jaimes DA, Londoño J, De Avila J, Castellanos JE, Bello JM, Bautista W, and Valle-Oñate R (2011) Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis. Clin Exp Rheumatol 29: 828-834.
119. Ross RL, Jones KD, Bennett RM, Ward RL, Druker BJ, and Wood LJ (2010) Preliminary evidence of increased pain and elevated cytokines in fibromyalgia patients with defective growth hormone response to exercise. Open Immunol J 3:9-18.
120. Rossini M, Di MO, Valentini G, Bianchi G, Biasi G, Cacace E, Malesci D, La MG, Viapiana O, and Adami S (2007) Double-blind, multicenter trial comparing acetyl lcarnitine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol 25:182-188.
121. Rottem M and Mekori YA (2005) Mast cells and autoimmunity. Autoimmun Rev 4: 21-27.
122. Russell IJ (1998) Advances in fibromyalgia: possible role for central neurochemicals. Am J Med Sci 315:377-384.
123. Russell IJ (2008) Fibromyalgia syndrome: Approach to management. CNS Spectr 13 (3, Suppl 5)27-33.
124. Russell IJ and Larson AA (2009) Neurophysiopathogenesis of fibromyalgia syndrome: A unified hypothesis. Rheum Dis Clin North Am 35:421-435.
125. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, and Arnold LM (2008) Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136: 432-444.
126. Sawynok J and Lynch M (2014) Qigong and fibromyalgia: randomized controlled trials and beyond. Evid Based Complement Alternat Med 2014:379715 DOI:10.1155/2014/379715.
127. Schmidt-Wilcke T and Clauw DJ (2011) Fibromyalgia: from pathophysiology to therapy. Nat Rev Rheumatol 7:518-527.
128. Scholzen TE, Steinhoff M, Bonaccorsi P, Klein R, Amadesi S, Geppetti P, Lu B, Gerard NP, Olerud JE, and Luger TA, et al. (2001) Neutral endopeptidase terminates substance P-induced inflammation in allergic contact dermatitis. J Immunol 166:1285-1291.
129. Smith SB, Maixner DW, Fillingim RB, Slade G, Gracely RH, Ambrose K, Zaykin DV, Hyde C, John S, and Tan K, et al. (2012) Large candidate gene association study reveals genetic risk factors and therapeutic targets for fibromyalgia. Arthritis Rheum 64:584-593.
130. Staud R (2011) Brain imaging in fibromyalgia syndrome. Clin Exp Rheumatol 29(6, Suppl 69)S109-S117.
131. Staud R, Vierck CJ, Cannon RL, Mauderli AP, and Price DD (2001) Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 91:165-175.
132. Tagen M, Elorza A, Kempuraj D, Boucher W, Kepley CL, Shirihai OS, and Theoharides TC (2009) Mitochondrial uncoupling protein 2 inhibits mast cell activation and reduces histamine content. J Immunol 183:6313-6319.
133. Taliou A, Zintzaras E, Lykouras L, and Francis K (2013) An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin Ther 35:592-602.
134. Theoharides TC (2013a) Atopic conditions in search of pathogenesis and therapy. Clin Ther 35:544-547.
135. Theoharides TC (2013b) Is a subtype of autism an allergy of the brain? Clin Ther 35: 584-591.
136. Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B, Asadi S, Vasiadi M, Weng Z, and Miniati A, et al. (2012a) Mast cells and inflammation. Biochim Biophys Acta 1822:21-33.
137. Theoharides TC, Angelidou A, Alysandratos KD, Zhang B, Asadi S, Francis K, Toniato E, and Kalogeromitros D (2012b) Mast cell activation and autism. Biochim Biophys Acta 1822:34-41.
138. Theoharides TC, Asadi S, Weng Z, and Zhang B (2011) Serotonin-selective reuptake inhibitors and nonsteroidal anti-inflammatory drugs-important considerations of adverse interactions especially for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome. J Clin Psychopharmacol 31:403-405.
139. Theoharides TC, Dimitriadou V, Letourneau R, Rozniecki JJ, Vliagoftis H, and Boucher W (1993) Synergistic action of estradiol and myelin basic protein on mast cell secretion and brain myelin changes resembling early stages of demyelination. Neuroscience 57:861-871.
140. Theoharides TC, Kempuraj D, Tagen M, Conti P, and Kalogeromitros D (2007) Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 217:65-78.
141. Theoharides TC and Konstantinidou AD (2007) Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosci 12:1615-1628.
142. Theoharides TC, Petra AI, Stewart JM, Tsilioni I, Panagiotidou S, and Akin C (2014) High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patient. J Allergy Clin Immunol 134: 1197-1199.
143. Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, and Conti P (2015a) The importance of IL-33 in allergic inflammation. J Pharmacol Exp Ther 354:24-31.
144. Theoharides TC, Stewart JM, Hatziagelaki E, and Kolaitis G (2015b) Brain "fog, " inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. Front Neurosci 9:225.
145. Theoharides TC, Valent P, and Akin C (2015c) Mast cells, mastocytosis and related diseases. N Engl J Med 373:163-172.
146. Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A, Alysandratos KD, Kalogeromitros D, Asadi S, and Stavrianeas N, et al. (2010) IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 107:4448-4453.
147. Togo F, Natelson BH, Adler GK, Ottenweller JE, Goldenberg DL, Struzik ZR, and Yamamoto Y (2009) Plasma cytokine fluctuations over time in healthy controls and patients with fibromyalgia. Exp Biol Med (Maywood) 234:232-240.
148. Torresani C, Bellafiore S, and De Panfilis G (2009) Chronic urticaria is usually associated with fibromyalgia syndrome. Acta Derm Venereol 89:389-392.
149. Tsilioni I, Panagiotidou S, and Theoharides TC (2014) Exosomes in neurologic and psychiatric disorders. Clin Ther 36:882-888.
150. Uçeyler N, Häuser W, and Sommer C (2011) Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord 12:245.
151. Vargas-Alarcón G, Fragoso JM, Cruz-Robles D, Vargas A, Martinez A, Lao-Villadóniga JI, García-Fructuoso F, Vallejo M, and Martínez-Lavín M (2009) Association of adrenergic receptor gene polymorphisms with different fibromyalgia syndrome domains. Arthritis Rheum 60:2169-2173.
152. Wallace DJ, Gavin IM, Karpenko O, Barkhordar F, and Gillis BS (2015) Cytokine and chemokine profiles in fibromyalgia, rheumatoid arthritis and systemic lupus erythematosus: A potentially useful tool in differential diagnosis. Rheumatol Int 35:991-996.
153. Wang P, Wu P, Siegel MI, Egan RW, and Billah MM (1995) Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL- 10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 270:9558-9563.
154. Weng Z, Patel A, Panagiotidou S, and Theoharides TC (2014a) The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol 14:01574-01577.
155. Weng Z, Patel AB, Vasiadi M, Therianou A, and Theoharides TC (2014b) Luteolin inhibits human keratinocyte activation and decreases NF-kB induction that is increased in psoriatic skin. PLoS One 9:e90739.
156. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, Mease P, Russell AS, Russell IJ, and Winfield JB (2011) Fibromyalgia criteria and severity scales for clinical and epidemiological studies: A modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol 38:1113-1122.
157. Wolfe F and Walitt B (2013) Culture, science and the changing nature of fibromyalgia. Nat Rev Rheumatol 9:751-755.
158. Woodman I (2013) Fibromyalgia: fibromyalgia-all in the brain? Nat Rev Rheumatol 9: 565.
159. Woolf CJ (2011) Central sensitization: implications for the diagnosis and treatment of pain. Pain 152(3, Suppl)S2-S15.
160. Yunus MB (2007) Fibromyalgia and overlapping disorders: The unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 36:339-356.
161. Zhang B, Asadi S, Weng Z, Sismanopoulos N, and Theoharides TC (2012) Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. PLoS One 7:e49767.
162. Zhang Z, Cherryholmes G, Mao A, Marek C, Longmate J, Kalos M, Amand RP, and Shively JE (2008) High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia. Exp Biol Med (Maywood) 233: 1171-1180.